Insulin efsitora alfa for insulin resistance

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 12 Apr 2024: Trial registered, NCT06362265
  2. 10 Oct 2024: Trial started, NCT06362265

The trials

NCT06362265: A Study to Evaluate Pharmacokinetics of LY3209590 in Pediatric Participants With Type 2 Diabetes Mellitus

State
Completed
Phase
Phase 1
People
15 taking part
Started
10 Oct 2024
Primary completion
2 Jan 2026
Arms
LY3209590
Results
None posted
  1. 12 Apr 2024: Trial registered
  2. 10 Oct 2024: Trial started
  3. 2 Jan 2026: Trial completed

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.